Fig 2.
(A) Prostate-specific antigen drift: A slow rise in PSA after an initial rapid decline with no evidence of radiographic or clinical progression for 28 months while receiving MDV3100; (B) an initial rapid rise in PSA with subsequent decline above baseline on a second value in a patient who remained biochemically, radiographically, and clinically stable for 22 months on abiraterone acetate.
